K2M

Although Stryker's other acquisitions failed to match the K2M deal value, they nonetheless were equally as important to the multinational's long-term growth strategy.

Upon closing, the selling stockholders will continue to beneficially own 5,486,263 shares, or approximately 13.0%, of K2M's outstanding common stock after giving effect to the offering (or 4,886,263 shares, or approximately 11.6%, if the underwriter fully exercises its option to purchase additional shares from the selling stockholders).

K2M Group Holdings (KTWO) up 4.5% after FDA cleared its Mesa technology platform...

Stryker Corporation added some heat to the summertime OEM buying spree by forking over $1.4 billion for K2M Group Holdings Inc., a key player in the $10 billion spinal market.

Stryker Corporation announced a definitive merger agreement to acquire K2M Group Holdings Inc.

The major players operating in this market are Arthrex, Inc., Cesca Therapeutics, Inc., DepuySynthes, Inc., DMP Spine, Exactech, Inc., K2m, Inc., Lattice Biologics, Medtronic, Nuo Therapeutics, Inc., Nutech, Nuvasive, Inc., Orthofix Holdings, Inc., Regen Lab Sa, RTI Surgical, Inc., Stryker Corporation, Wright Medical Technology, Inc., X-Spine Systems, Inc., Zimmer Holdings, Inc., among other companies.

Major companies operational in the spine biologics market are Medtronic Inc., DePuy Synthes Companies, Zimmer Holding Inc., Nuvasive Inc., Stryker Corp., Orthofix International N.V., K2M Inc., Exactech Inc., Wright Medical Technology Inc., and others.

Medical device company K2M Group Holdings (NasdaqGS:KTWO) reported on Monday the sale of 750,000 shares plus selling stockholders' 3,750,000 shares at a price to the public of USD22.60 per share.

- WELSH CARSON TO TAKE CONTROL OF MEDICAL DEVICE FIRM K2M

K2M Group Holdings announced at the Scoliosis Research Society 53rd Annual Meeting & Course, in Bologna, Italy a FDA clearance that also provides for the Dual Differential Correction Philosophy & Technique.